Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Shiffman · SciRah

Researcher profile · Semantic Scholar

M. Shiffman

Share profile

M. Shiffman — researcher profile on SciRah

h-index: 77
Works: 433
Citations: 35K

Most-cited papers

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
F. Nevens, P. Andreone, G. Mazzella, S. Strasser +28 more
2016New England Journal of Medicine981 citations Open access
Semantic Scholar
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
G. Foster, N. Afdhal, S. Roberts, N. Bräu +31 more
2015New England Journal of Medicine950 citations Open access
Semantic Scholar
Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
Stephen A. Harrison, V. Wong, T. Okanoue, N. Bzowej +23 more
2020Journal of Hepatology429 citations
Semantic Scholar
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response
N. Terrault, S. Zeuzem, A. Di Bisceglie, Joseph K. Lim +11 more
2016Gastroenterology353 citations Open access
Semantic Scholar
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Stephen A. Harrison, M. Abdelmalek, S. Caldwell, M. Shiffman +17 more
2018Gastroenterology344 citations Open access
Semantic Scholar
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
A. J. Sanyal, S. Harrison, V. Ratziu, M. Abdelmalek +15 more
2019Hepatology329 citations
Semantic Scholar
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension.
N. Chalasani, M. Abdelmalek, G. Garcia-Tsao, R. Vuppalanchi +14 more
2019Gastroenterology316 citations Open access
Semantic Scholar
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
K. Patel, S. Harrison, M. Elkhashab, J. Trotter +20 more
2020Hepatology305 citations
Semantic Scholar
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
R. Loomba, M. Noureddin, Kris V. Kowdley, A. Kohli +30 more
2020Hepatology254 citations
Semantic Scholar
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
M. Trauner, A. Gulamhusein, B. Hameed, S. Caldwell +16 more
2019Hepatology237 citations Open access
Semantic Scholar
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
David E. J. Jones, P. Boudes, M. Swain, C. Bowlus +32 more
2017The Lancet Gastroenterology and Hepatology166 citations Open access
Semantic Scholar
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease
Andrew J. Muir, C. Levy, H. L. A. Janssen, A. Montano-Loza +15 more
2019Hepatology155 citations
Semantic Scholar
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.
M. Trauner, F. Nevens, M. Shiffman, J. Drenth +8 more
2019The Lancet Gastroenterology and Hepatology148 citations Open access
Semantic Scholar
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease
M. Shiffman, B. Freilich, R. Vuppalanchi, K. Watt +4 more
2018Alimentary Pharmacology and Therapeutics100 citations Open access
Semantic Scholar
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End‐Stage Liver Disease Scores Compared With Placebo
C. Frenette, G. Morelli, M. Shiffman, Todd Frederick +13 more
2019Clinical Gastroenterology and Hepatology99 citations Open access
Semantic Scholar
Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.
Z. Younossi, M. Noureddin, D. Bernstein, P. Kwo +4 more
2020American Journal of Gastroenterology96 citations Open access
Semantic Scholar
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
G. Hirschfield, M. Shiffman, A. Gulamhusein, K. Kowdley +36 more
2023Hepatology80 citations Open access
Semantic Scholar
Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
G. Garcia-Tsao, M. Fuchs, M. Shiffman, B. Borg +11 more
2018Hepatology77 citations Open access
Semantic Scholar
Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment
R. Wong, M. Jain, G. Therapondos, M. Shiffman +3 more
2018American Journal of Gastroenterology77 citations
Semantic Scholar
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
T. Ahmad, P. Yin, J. Saffitz, P. Pockros +13 more
2015Hepatology74 citations
Semantic Scholar
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
C. Bowlus, M. Galamboš, R. Aspinall, G. Hirschfield +20 more
2022Journal of Hepatology73 citations Open access
Semantic Scholar
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis
J. Bosch, C. Chung, Oscar Carrasco-Zevallos, S. Harrison +17 more
2021Hepatology62 citations Open access
Semantic Scholar
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
E. Lawitz, N. Reau, F. Hinestrosa, M. Rabinovitz +19 more
2016Gastroenterology55 citations Open access
Semantic Scholar
The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.
Nadege T. Gunn, M. Shiffman
2018Clinical Liver Disease53 citations
Semantic Scholar
Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study
E. Gane, M. Shiffman, K. Etzkorn, G. Morelli +11 more
201651 citations
Semantic Scholar
Management of hepatitis C virus infection in the Asia-Pacific region: an update.
Seng G. Lim, A. Aghemo, Pei-Jer Chen, Y. Dan +14 more
2017The Lancet Gastroenterology and Hepatology50 citations
Semantic Scholar
Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct‐Acting‐Antiviral Period?
M. Jain, M. Thamer, G. Therapondos, M. Shiffman +3 more
2018Hepatology45 citations
Semantic Scholar
Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC.
M. Trauner, C. Bowlus, A. Gulamhusein, B. Hameed +11 more
2022Clinical Gastroenterology and Hepatology37 citations
Semantic Scholar
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
Z. Younossi, M. Stepanova, M. Noureddin, K. Kowdley +13 more
2021Hepatology Communications32 citations Open access
Semantic Scholar
LP37 : A placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases
M. Shiffman, B. Freilich, R. Vuppalanchi, K. Watt +4 more
201529 citations
Semantic Scholar
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials
E. Gane, V. de Lédinghen, D. Dylla, G. Rizzardini +6 more
2021Journal of Viral Hepatitis27 citations Open access
Semantic Scholar
100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Naïve HCV Genotype 3-Infected Patients with Cirrhosis
P. Kwo, D. Wyles, Stanley Wang, F. Poordad +8 more
201623 citations
Semantic Scholar
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients with Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Joseph K. Lim, Annmarie Liapakis, M. Shiffman, A. Lok +14 more
2018Clinical Gastroenterology and Hepatology22 citations Open access
Semantic Scholar
Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials
A. Sanyal, M. Abdelmalek, A. Diehl, S. Caldwell +15 more
201722 citations
Semantic Scholar
SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy
J. Grebely, I. Jacobson, Z. Kayali, E. Verna +10 more
201720 citations
Semantic Scholar
Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
A. Parés, M. Shiffman, V. Vargas, P. Invernizzi +4 more
2020Liver international (Print)17 citations Open access
Semantic Scholar
Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C)
F. Poordad, M. Shiffman, W. Ghesquière, A. Wong +8 more
2019Antiviral Therapy13 citations Open access
Semantic Scholar
Approach to the patient with chronic hepatitis B and decompensated cirrhosis
M. Shiffman
2020Liver international (Print)12 citations
Semantic Scholar
Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis
A. Sanyal, S. Harrison, V. Ratziu, M. Abdelmalek +14 more
201711 citations
Semantic Scholar
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort
G. Foster, C. Coppola, M. Derbala, P. Ferenci +7 more
2016PLoS ONE11 citations Open access
Semantic Scholar
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents
M. Shiffman, V. Rustgi, M. Bennett, X. Forns +6 more
2016American Journal of Gastroenterology11 citations Open access
Semantic Scholar
The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong
P. Kwo, M. Shiffman, D. Bernstein
2018American Journal of Gastroenterology10 citations
Semantic Scholar
A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
R. Flisiak, M. Shiffman, J. Arenas, H. Cheinquer +4 more
2016PLoS ONE10 citations Open access
Semantic Scholar
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study
M. Sulkowski, Juhi Moon, K. Sherman, G. Morelli +23 more
2021Hepatology9 citations Open access
Semantic Scholar
The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC.
M. Trauner, A. Gulamhusein, B. Hameed, S. Caldwell +16 more
20197 citations
Semantic Scholar
THU-138-High efficacy and improvement in CPT class with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with CPT C decompensated cirrhosis
S. Flamm, E. Lawitz, B. Borg, M. Charlton +12 more
2019Journal of Hepatology6 citations
Semantic Scholar
Scheuer’s Liver Biopsy Interpretation, 9th Edition
M. Shiffman
20176 citations Open access
Semantic Scholar
A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
T. Asselah, A. Thompson, R. Flisiak, M. Romero-Gómez +3 more
2016PLoS ONE6 citations Open access
Semantic Scholar
Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment.
R. Wong, M. Jain, G. Therapondos, M. Shiffman +3 more
2020Journal of Clinical and Experimental Hepatology5 citations Open access
Semantic Scholar
Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial
R. Loomba, M. Noureddin, K. Kowdley, A. Kohli +29 more
2020Journal of Hepatology5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Z. Goodman×11
Invite
Z. Goodman — researcher profile on SciRah
C. Bowlus×9
Invite
C. Bowlus — researcher profile on SciRah
J. Mchutchison×9
Invite
J. Mchutchison — researcher profile on SciRah
C. Jia×9
Invite
C. Jia — researcher profile on SciRah

×9

Invite

S. Caldwell — researcher profile on SciRah

Invite

E. Lawitz — researcher profile on SciRah

Invite

R. Myers — researcher profile on SciRah

Invite

N. Afdhal — researcher profile on SciRah

M. Abdelmalek×7

Invite

M. Abdelmalek — researcher profile on SciRah

Invite

C. Chung — researcher profile on SciRah

Invite

M. Trauner — researcher profile on SciRah

G. Hirschfield×6

Invite

G. Hirschfield — researcher profile on SciRah